Q1 Earnings Estimate for Beam Therapeutics Issued By Wedbush

Beam Therapeutics Inc. (NASDAQ:BEAM) – Stock analysts at Wedbush lowered their Q1 2025 earnings per share (EPS) estimates for shares of Beam Therapeutics in a research note issued to investors on Tuesday, February 25th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($1.21) for the quarter, down from their prior estimate of ($1.16). Wedbush has a “Outperform” rating and a $57.00 price objective on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. Wedbush also issued estimates for Beam Therapeutics’ Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($1.18) EPS, Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($4.81) EPS, FY2026 earnings at ($5.60) EPS, FY2027 earnings at ($5.42) EPS and FY2028 earnings at ($4.15) EPS.

Beam Therapeutics (NASDAQ:BEAM) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($1.09) EPS for the quarter, beating analysts’ consensus estimates of ($1.25) by $0.16. The firm had revenue of $30.00 million for the quarter, compared to analyst estimates of $16.47 million. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The business’s quarterly revenue was down 90.5% compared to the same quarter last year. During the same period last year, the company earned $1.73 EPS.

A number of other research analysts also recently weighed in on BEAM. Sanford C. Bernstein raised Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 7th. Leerink Partnrs raised Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Guggenheim reissued a “buy” rating and issued a $78.00 price target on shares of Beam Therapeutics in a research note on Thursday. Leerink Partners raised Beam Therapeutics from a “market perform” rating to an “outperform” rating and increased their price target for the company from $27.00 to $39.00 in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada increased their price target on Beam Therapeutics from $24.00 to $26.00 and gave the company a “sector perform” rating in a research note on Wednesday. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $50.90.

Beam Therapeutics Stock Down 2.8 %

BEAM stock opened at $27.11 on Thursday. The business’s fifty day moving average is $27.22 and its 200-day moving average is $25.91. The company has a market cap of $2.24 billion, a P/E ratio of -15.40 and a beta of 1.92. Beam Therapeutics has a twelve month low of $20.84 and a twelve month high of $45.79.

Insider Buying and Selling

In other Beam Therapeutics news, insider Christine Bellon sold 1,241 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $24.68, for a total transaction of $30,627.88. Following the completion of the transaction, the insider now owns 102,968 shares in the company, valued at approximately $2,541,250.24. This represents a 1.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John M. Evans sold 30,000 shares of the stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $26.75, for a total value of $802,500.00. Following the transaction, the chief executive officer now owns 908,659 shares of the company’s stock, valued at approximately $24,306,628.25. This trade represents a 3.20 % decrease in their position. The disclosure for this sale can be found here. 4.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Beam Therapeutics

Large investors have recently added to or reduced their stakes in the company. Wealthfront Advisers LLC bought a new position in Beam Therapeutics during the 4th quarter worth about $41,000. GF Fund Management CO. LTD. bought a new position in Beam Therapeutics during the 4th quarter worth about $43,000. Sterling Capital Management LLC increased its holdings in Beam Therapeutics by 816.0% during the 4th quarter. Sterling Capital Management LLC now owns 2,409 shares of the company’s stock worth $60,000 after purchasing an additional 2,146 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Beam Therapeutics by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,981 shares of the company’s stock worth $75,000 after purchasing an additional 524 shares in the last quarter. Finally, Blue Trust Inc. grew its holdings in shares of Beam Therapeutics by 84.0% in the 3rd quarter. Blue Trust Inc. now owns 3,135 shares of the company’s stock valued at $73,000 after acquiring an additional 1,431 shares in the last quarter. Institutional investors own 99.68% of the company’s stock.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.